Comparison of Efficacy in Patients with Metastatic Melanoma Treated with Ipilimumab and Nivolumab Who Did or Did Not Discontinue Treatment Due to Immune-Related Adverse Events: A Real-World Data Study

SIMPLE SUMMARY: This retrospective study of real-world patients with metastatic melanoma shows that discontinuing treatment with combination immunotherapy due to adverse events does not result in a poorer outcome compared to patients that did not discontinue due to toxicity. This is important knowle...

Descripción completa

Detalles Bibliográficos
Autores principales: Fink, Morten, Vittrup, Anders Schwartz, Bastholt, Lars, Svane, Inge Marie, Donia, Marco, Luczak, Adam A., Ruhlmann, Christina H., Guldbrandt, Louise Mahncke, Koehler, Ulrich Heide, Winther, Mette Lerche, Ellebaek, Eva, Haslund, Charlotte Aaquist, Schmidt, Henrik
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583558/
https://www.ncbi.nlm.nih.gov/pubmed/34771712
http://dx.doi.org/10.3390/cancers13215550

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8583558/
https://www.ncbi.nlm.nih.gov/pubmed/34771712
http://dx.doi.org/10.3390/cancers13215550

Ejemplares similares